<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01085721</url>
  </required_header>
  <id_info>
    <org_study_id>POE/P/09-1</org_study_id>
    <nct_id>NCT01085721</nct_id>
  </id_info>
  <brief_title>Comparison Between Dexchlorpheniramine and Dexchlorpheniramine/Pseudoephedrine/Guaifenesin in Respiratory Infections</brief_title>
  <official_title>Comparison Between Dexchlorpheniramine and Dexchlorpheniramine/Pseudoephedrine/Guaifenesin in the Relief of Allergic Symptoms in Rhinitic Patients With Viral Upper Respiratory Tract Infections and Productive Cough</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mantecorp Industria Quimica e Farmaceutica Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mantecorp Industria Quimica e Farmaceutica Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with allergic rhinitis frequently present exacerbation of the atopic symptoms during
      viral infections of the upper respiratory tract. Also, allergic rhinitis makes the mucosa
      more reactive to infectious agents and potentiates mucus production.

      The combination of dexchlorpheniramine, pseudoephedrine and guaifenesin elicits
      antihistaminic, decongestant and expectorant effects. The study hypothesizes is that this
      product is superior to dexchlorpheniramine alone in the relief of allergic symptoms and in
      promoting mucus elimination in atopic patients with viral infections of the upper respiratory
      tract.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms frequency and intensity evaluated with a 5 point visual analogic scale (VAS)</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective evaluation of efficacy and tolerability graded as excellent, good, fair ou poor.</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Viral Infections of the Upper Respiratory Tract</condition>
  <arm_group>
    <arm_group_label>Dexchlorpheniramine pseudoephedrine guaifenesin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexchlorpheniramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexchlorpheniramine, pseudoephedrine, guaifenesin</intervention_name>
    <description>5 mL (2 mg dexchlorpheniramine, 20 mg pseudoephedrine and 100 mg guaifenesin) qid for 5 days</description>
    <arm_group_label>Dexchlorpheniramine pseudoephedrine guaifenesin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexchlorpheniramine</intervention_name>
    <description>5 mL (2 mg dexchlorpheniramine) qid for 5 days</description>
    <arm_group_label>Dexchlorpheniramine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with allergic rhinitis with symptoms of viral infection of the upper
             respiratory tract (rhinorrhea, nasal obstruction and productive cough)

          -  Compliance of the subject to the treatment protocol

          -  Agreement with the terms of the informed consent

          -  Patients who did not use forbidden medications

        Exclusion Criteria:

          -  History of allergy to any component of the formulations

          -  Use of any investigational drug within the last 30 days

          -  Patients with bacterial infections of the upper respiratory tract

          -  Patients with high blood pressure (&gt; 140 x 90 mmHg)

          -  Patients who are receiving inhaled beta-agonists or other antihistamine, decongestant
             or expectorant

          -  Patients with known pulmonary disease (asthma, COPD, neoplasias)

          -  Pregnancy

          -  HIV + patients

          -  Other conditions considered by the investigator as reasonable for non-eligibility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Claudia Domingues</last_name>
    <phone>+551151885237</phone>
    <email>cdomingues@mantecorp.com</email>
  </overall_contact>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2010</study_first_posted>
  <last_update_submitted>March 10, 2010</last_update_submitted>
  <last_update_submitted_qc>March 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Celso Pereira Sustovich, Medical Director</name_title>
    <organization>Mantecorp Indústria Química e Farmacêutica Ltda.</organization>
  </responsible_party>
  <keyword>allergic rhinitis</keyword>
  <keyword>viral infections of the upper respiratory tract</keyword>
  <keyword>dexchlorpheniramine</keyword>
  <keyword>pseudoephedrine</keyword>
  <keyword>guaifenesin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Phenylpropanolamine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
    <mesh_term>Guaifenesin</mesh_term>
    <mesh_term>Dexchlorpheniramine</mesh_term>
    <mesh_term>Chlorpheniramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

